BRISTOL-MYERS SQUIBB COMPANY | 33,72 Euro | -0,675 -1,96 % | |
| WKN: 850501 ISIN: US1101221083 Ticker-Symbol: BRM | Xetra | 17.05.13 | 15:31 Uhr |
Branche PharmaAktienmarkt S&P 100S&P 500 |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 17.05. | Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buy | 27 | Seeking Alpha | |
| 16.05. | Bristol-Myers Squibb's drug combo can shrink cancer tumors | 1 | bizjournals | |
| 16.05. | Leerink stuft Bristol-Myers von Market Perform auf Outperform. | 101 | BörseGo | |
| Leerink stuft Bristol-Myers von Market Perform auf Outperform.
(© BörseGo AG 2013 - Autor: Simon Hauser, Redakteur) Mehr lesen zu: Leerink stuft Bristol-Myers von Market Perform auf Outperform. | ||||
| 16.05. | Erfolg für BRISTOL-MYERS | 130 | Bernecker Börsenbriefe | |
| Das hört sich gut an: Bristol-Myers Squibb hat Erfolge bei der Erprobung einer neuer Methode zur Behandlung von schwarzem Hautkrebs mit einer Kombination von zwei Medikamenten vermeldet. Der Pharmakonzern... Mehr lesen zu: Erfolg für BRISTOL-MYERS | ||||
| 16.05. | Bristol-Myers meldet Erfolg beim Test von Hautkrebs-Medikamenten | 8 | Reuters Deutschland | |
| 16.05. | With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What | 3 | Forbes | |
| 16.05. | Bristol-Myers Drug Cocktail Stymies Melanoma Tumors | 3 | Bloomberg | |
| 15.05. | UPDATE 1-Bristol-Myers shares jump ahead of melanoma trial data | 2 | Reuters.com | |
| 15.05. | Bristol-Myers shares jump ahead of melanoma trial data | 2 | Reuters.com | |
| 15.05. | Shares of Bristol-Myers Squibb Are Up on Strong Volume | - | SmarTrend | |
| 15.05. | Busy Day For Bristol-Myers Options As Shares Sprint Higher | 1 | Seeking Alpha | |
| 15.05. | Bristol-Myers Targets Heart-Failure Drugs in R&D Effort | 9 | Bloomberg | |
| 15.05. | Shares of Bristol-Myers Squibb Rise to a New 52-Week High | - | SmarTrend | |
| 10.05. | BRISTOL MYERS SQUIBB CO - 8-K, Current Report | 4 | SEC Filings | |
| 10.05. | Adaptive signs biomarker discovery partnership in oncology with Bristol-Myers | 1 | Pharma Bus Review | |
| 09.05. | Next Support Level for Bristol-Myers Squibb is $39.41 | - | SmarTrend | |
| 09.05. | Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb | 86 | PR Newswire | |
| SEATTLE, May 9, 2013 /PRNewswire/ --Adaptive Biotechnologies announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers... Mehr lesen zu: Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb | ||||
| 09.05. | Bristol-Myers, Disney, Google: Intellectual Property | - | Bloomberg | |
| 07.05. | Bristol-Myers, Pfizer Announce Results From Subanalysis Of ARISTOTLE Trial | 64 | AFX News | |
| NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and Pfizer Inc.
(PFE) said Tuesday that results from a prespecified subanalysis of the ARISTOTLE
trial showed that the reductions... Mehr lesen zu: Bristol-Myers, Pfizer Announce Results From Subanalysis Of ARISTOTLE Trial | ||||
| 07.05. | The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie, Celgene and Telus | 234 | PR Newswire | |
| CHICAGO, May 7, 2013 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks... Mehr lesen zu: The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie, Celgene and Telus | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| PFIZER | 22,565 | -1,03 % | Global Vision Selected by Pfizer for Worldwide Deployment of Automated Proofreading Solutions |
| NOVARTIS | 57,46 | -1,61 % | Gericht prüft Klage von Pharmakonzern Novartis gegen Bewertung |
| MERCK & CO | 35,438 | -1,64 % | Merck Prices $6.5 Bln Debt Offering |
| GLAXOSMITHKLINE | 20,26 | -0,34 % | Berenberg hebt Ziel für GlaxoSmithKline auf 1.870 Pence - 'Buy' |
| ASTRAZENECA | 40,101 | -0,35 % | Berenberg hebt Ziel für AstraZeneca auf 3.425 Pence - 'Hold' |
